Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts.
Diagnosis
Early Detection
Pancreas
Pancreatic Cancer
Pancreatic Neoplasm
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
20
12
2021
revised:
22
08
2022
accepted:
16
09
2022
pmc-release:
01
01
2024
pubmed:
10
10
2022
medline:
21
12
2022
entrez:
9
10
2022
Statut:
ppublish
Résumé
Next-generation sequencing (NGS) of pancreatic cyst fluid is a useful adjunct in the assessment of patients with pancreatic cyst. However, previous studies have been retrospective or single institutional experiences. The aim of this study was to prospectively evaluate NGS on a multi-institutional cohort of patients with pancreatic cyst in real time. The performance of a 22-gene NGS panel (PancreaSeq) was first retrospectively confirmed and then within a 2-year timeframe, PancreaSeq testing was prospectively used to evaluate endoscopic ultrasound-guided fine-needle aspiration pancreatic cyst fluid from 31 institutions. PancreaSeq results were correlated with endoscopic ultrasound findings, ancillary studies, current pancreatic cyst guidelines, follow-up, and expanded testing (Oncomine) of postoperative specimens. Among 1933 PCs prospectively tested, 1887 (98%) specimens from 1832 patients were satisfactory for PancreaSeq testing. Follow-up was available for 1216 (66%) patients (median, 23 months). Based on 251 (21%) patients with surgical pathology, mitogen-activated protein kinase/GNAS mutations had 90% sensitivity and 100% specificity for a mucinous cyst (positive predictive value [PPV], 100%; negative predictive value [NPV], 77%). On exclusion of low-level variants, the combination of mitogen-activated protein kinase/GNAS and TP53/SMAD4/CTNNB1/mammalian target of rapamycin alterations had 88% sensitivity and 98% specificity for advanced neoplasia (PPV, 97%; NPV, 93%). Inclusion of cytopathologic evaluation to PancreaSeq testing improved the sensitivity to 93% and maintained a high specificity of 95% (PPV, 92%; NPV, 95%). In comparison, other modalities and current pancreatic cyst guidelines, such as the American Gastroenterology Association and International Association of Pancreatology/Fukuoka guidelines, show inferior diagnostic performance. The sensitivities and specificities of VHL and MEN1/loss of heterozygosity alterations were 71% and 100% for serous cystadenomas (PPV, 100%; NPV, 98%), and 68% and 98% for pancreatic neuroendocrine tumors (PPV, 85%; NPV, 95%), respectively. On follow-up, serous cystadenomas with TP53/TERT mutations exhibited interval growth, whereas pancreatic neuroendocrine tumors with loss of heterozygosity of ≥3 genes tended to have distant metastasis. None of the 965 patients who did not undergo surgery developed malignancy. Postoperative Oncomine testing identified mucinous cysts with BRAF fusions and ERBB2 amplification, and advanced neoplasia with CDKN2A alterations. PancreaSeq was not only sensitive and specific for various pancreatic cyst types and advanced neoplasia arising from mucinous cysts, but also reveals the diversity of genomic alterations seen in pancreatic cysts and their clinical significance.
Sections du résumé
BACKGROUND & AIMS
Next-generation sequencing (NGS) of pancreatic cyst fluid is a useful adjunct in the assessment of patients with pancreatic cyst. However, previous studies have been retrospective or single institutional experiences. The aim of this study was to prospectively evaluate NGS on a multi-institutional cohort of patients with pancreatic cyst in real time.
METHODS
The performance of a 22-gene NGS panel (PancreaSeq) was first retrospectively confirmed and then within a 2-year timeframe, PancreaSeq testing was prospectively used to evaluate endoscopic ultrasound-guided fine-needle aspiration pancreatic cyst fluid from 31 institutions. PancreaSeq results were correlated with endoscopic ultrasound findings, ancillary studies, current pancreatic cyst guidelines, follow-up, and expanded testing (Oncomine) of postoperative specimens.
RESULTS
Among 1933 PCs prospectively tested, 1887 (98%) specimens from 1832 patients were satisfactory for PancreaSeq testing. Follow-up was available for 1216 (66%) patients (median, 23 months). Based on 251 (21%) patients with surgical pathology, mitogen-activated protein kinase/GNAS mutations had 90% sensitivity and 100% specificity for a mucinous cyst (positive predictive value [PPV], 100%; negative predictive value [NPV], 77%). On exclusion of low-level variants, the combination of mitogen-activated protein kinase/GNAS and TP53/SMAD4/CTNNB1/mammalian target of rapamycin alterations had 88% sensitivity and 98% specificity for advanced neoplasia (PPV, 97%; NPV, 93%). Inclusion of cytopathologic evaluation to PancreaSeq testing improved the sensitivity to 93% and maintained a high specificity of 95% (PPV, 92%; NPV, 95%). In comparison, other modalities and current pancreatic cyst guidelines, such as the American Gastroenterology Association and International Association of Pancreatology/Fukuoka guidelines, show inferior diagnostic performance. The sensitivities and specificities of VHL and MEN1/loss of heterozygosity alterations were 71% and 100% for serous cystadenomas (PPV, 100%; NPV, 98%), and 68% and 98% for pancreatic neuroendocrine tumors (PPV, 85%; NPV, 95%), respectively. On follow-up, serous cystadenomas with TP53/TERT mutations exhibited interval growth, whereas pancreatic neuroendocrine tumors with loss of heterozygosity of ≥3 genes tended to have distant metastasis. None of the 965 patients who did not undergo surgery developed malignancy. Postoperative Oncomine testing identified mucinous cysts with BRAF fusions and ERBB2 amplification, and advanced neoplasia with CDKN2A alterations.
CONCLUSIONS
PancreaSeq was not only sensitive and specific for various pancreatic cyst types and advanced neoplasia arising from mucinous cysts, but also reveals the diversity of genomic alterations seen in pancreatic cysts and their clinical significance.
Identifiants
pubmed: 36209796
pii: S0016-5085(22)01086-1
doi: 10.1053/j.gastro.2022.09.028
pmc: PMC9844531
mid: NIHMS1859817
pii:
doi:
Substances chimiques
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-133.e7Subventions
Organisme : NCI NIH HHS
ID : R37 CA263622
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA200466
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Clin Gastroenterol Hepatol. 2012 Feb;10(2):192-8, 198.e1-2
pubmed: 21982970
AJR Am J Roentgenol. 2008 Sep;191(3):802-7
pubmed: 18716113
Gut. 2018 Dec;67(12):2131-2141
pubmed: 28970292
J Pathol. 2014 Jul;233(3):217-27
pubmed: 24604757
Oncologist. 2020 Feb;25(2):e276-e283
pubmed: 32043766
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21188-93
pubmed: 22158988
Am J Gastroenterol. 2010 Sep;105(9):2079-84
pubmed: 20354507
Gut. 2022 May;71(5):961-973
pubmed: 33849943
Gastrointest Endosc. 2003 Jul;58(1):59-64
pubmed: 12838222
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Gastroenterology. 2019 May;156(7):2024-2040
pubmed: 30721664
J Clin Endocrinol Metab. 2013 Dec;98(12):4784-9
pubmed: 24057286
NPJ Genom Med. 2018 Jul 20;3:18
pubmed: 30062048
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316009
Contemp Clin Trials. 2020 Oct;97:106144
pubmed: 32920242
Ann Surg. 2020 Mar;271(3):566-573
pubmed: 30339629
Am J Gastroenterol. 2013 Oct;108(10):1546-50
pubmed: 24091499
JAMA Surg. 2021 May 1;156(5):412-413
pubmed: 33439231
Gastroenterology. 2014 Feb;146(2):453-60.e5
pubmed: 24148618
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Neuro Oncol. 2016 Mar;18(3):379-87
pubmed: 26681766
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
Surgery. 2013 Oct;154(4):794-800; discussion 800-2
pubmed: 24074417
Ann Surg Oncol. 2016 Apr;23(4):1361-70
pubmed: 26597365
J Gastrointest Surg. 2016 Feb;20(2):277-83
pubmed: 26691146
Gastroenterology. 2015 Apr;148(4):824-48.e22
pubmed: 25805376
Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21
pubmed: 16135927
Am J Gastroenterol. 2018 Apr;113(4):464-479
pubmed: 29485131
Mod Pathol. 2021 Feb;34(2):438-444
pubmed: 32792597
Pancreatology. 2020 Apr;20(3):505-510
pubmed: 31948794
Mod Pathol. 2013 Nov;26(11):1478-87
pubmed: 23743931
Cancer Cytopathol. 2017 Jan;125(1):41-47
pubmed: 27647802
Cancer Cytopathol. 2010 Feb 25;118(1):1-13
pubmed: 20043327
Ann Surg Oncol. 2008 Nov;15(11):3187-92
pubmed: 18766406
Pancreatology. 2010;10(6):695-701
pubmed: 21242709
Endosc Int Open. 2017 Feb;5(2):E116-E122
pubmed: 28210708
Hum Pathol. 2022 Nov;129:11-20
pubmed: 35872157
Gastroenterology. 2020 Feb;158(3):573-582.e2
pubmed: 31678302
Sci Transl Med. 2011 Jul 20;3(92):92ra66
pubmed: 21775669
Ann Surg Oncol. 2019 Dec;26(13):4522-4536
pubmed: 31617119
Gastroenterology. 2019 Jun;156(8):2242-2253.e4
pubmed: 30836094
Mod Pathol. 2010 Jun;23(6):824-33
pubmed: 20305616
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Gastroenterology. 2015 Nov;149(6):1501-10
pubmed: 26253305
Clin Cancer Res. 2014 Aug 15;20(16):4381-9
pubmed: 24938521
Gastrointest Endosc. 2016 Jun;83(6):1107-1117.e2
pubmed: 26709110
Gastroenterology. 2018 Jun;154(8):2060-2063.e8
pubmed: 29486199
J Mol Diagn. 2015 Jan;17(1):53-63
pubmed: 25468433
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719
Am J Gastroenterol. 2007 Oct;102(10):2339-49
pubmed: 17764489
Gastrointest Endosc. 2016 Jan;83(1):140-8
pubmed: 26253016